Nizoblue (Ketoconazole)

Ketoconazole belongs to the imidazole class of antifungals. It inhibits the fungal enzyme lanosterol 14α‑demethylase, a key step in the synthesis of ergosterol, the sterol component of fungal cell membranes. Disruption of ergosterol production compromises membrane integrity, leading to fungal cell death and clearance of the infection.

The dosage of Nizoblue is determined by the prescribing clinician based on the specific infection, its severity and the patient’s age and skin condition. Typically, a thin layer is applied to the affected area once or twice daily for the period recommended by the healthcare professional. No universal regimen is provided here.

The safety of ketoconazole topical use during pregnancy and lactation has not been definitively established, and the product is classified as pregnancy category unknown. Healthcare providers should weigh the potential benefits against any possible risks and consider alternative treatments when treating pregnant or nursing patients.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other topical antifungals such as clotrimazole or terbinafine, ketoconazole offers a broad spectrum against dermatophytes, yeasts and some moulds. Its imidazole class provides both fungistatic and fungicidal activity, and it is particularly effective for seborrheic dermatitis. Choice of therapy depends on the pathogen, site of infection and patient tolerance.

Nizoblue should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the container tightly closed when not in use and avoid exposing the product to extreme temperatures, which could affect its stability and efficacy.

The product is applied topically to clean, dry skin. A thin layer is spread over the affected area and gently rubbed in, usually once or twice daily as directed by a healthcare professional. Hands should be washed after application, and the treated skin should not be covered with occlusive dressings unless advised.

Although rare, serious adverse reactions can include severe allergic responses such as contact urticaria, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. Systemic absorption may lead to hepatic dysfunction, especially with extensive or prolonged use. Patients should discontinue use and seek immediate medical attention if they experience widespread rash, blistering, fever or jaundice.

Nizoblue is contraindicated in individuals with a known hypersensitivity to ketoconazole, other imidazole antifungals, or any component of the formulation. It should also be avoided on large areas of damaged or inflamed skin, and in patients with pre‑existing liver disease when systemic absorption is a concern. Consultation with a healthcare professional is essential before initiating therapy.